3,911
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Effects of feminine hygiene products on the vaginal mucosal biome

, , M.A., , Ph.D. & , M.D., Ph.D.
Article: 19703 | Received 19 Sep 2012, Accepted 21 Jan 2013, Published online: 25 Feb 2013

References

  • Hainer BL, Gibson MV. Vaginitis: diagnosis and treatment. Am Fam Physician. 2011; 83: 807–15.
  • Fichorova RN, Onderdonk AB, Yamamoto H, Delaney ML, Dubois AM, Allred E, et al. Maternal microbe-specific modulation of inflammatory response in extremely low-gestational-age newborns. mBio. 2011; 2: e00280–10.
  • Larsson PG, Bergstrom M, Forsum U, Jacobsson B, Strand A, Wolner-Hanssen P. Bacterial vaginosis. Transmission, role in genital tract infection and pregnancy outcome: an enigma. APMIS. 2005; 113: 233–45. 10.3402/mehd.v24i0.19703.
  • Antonio MA, Hawes SE, Hillier SL. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis. 1999; 180: 1950–6. 10.3402/mehd.v24i0.19703.
  • Verstraelen H, Verhelst R, Claeys G, De Backer E, Temmerman M, Vaneechoutte M. Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiol. 2009; 9: 116. 10.3402/mehd.v24i0.19703.
  • Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011; 52: 1212–7. 10.3402/mehd.v24i0.19703.
  • Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane database of systematic reviews (Online). 2009: CD006289.
  • Graver MA, Wade JJ. The role of acidification in the inhibition of Neisseria gonorrhoeae by vaginal lactobacilli during anaerobic growth. Ann Clin Microbiol Antimicrob. 2011; 10: 8. 10.3402/mehd.v24i0.19703.
  • Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr. 2005; 39: 1–8. 10.3402/mehd.v24i0.19703.
  • Fichorova RN, Tucker L, Anderson DJ. The molecular basis of nonoxynol-9 induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis. 2001; 184: 418–28. 10.3402/mehd.v24i0.19703.
  • Trifonova RT, Pasicznyk JM, Fichorova RN. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Antimicrob Agents Chemother. 2006; 50: 4005–10. 10.3402/mehd.v24i0.19703.
  • Fichorova RN, Rheinwald JG, Anderson DJ. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol Reprod. 1997; 57: 847–55. 10.3402/mehd.v24i0.19703.
  • Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod. 2004; 71: 761–9. 10.3402/mehd.v24i0.19703.
  • Onderdonk AB, Zamarchi GR, Rodriguez ML, Hirsch ML, Munoz A, Kass EH. Qualitative assessment of vaginal microflora during use of tampons of various compositions. Appl Environ Microbiol. 1987; 53: 2779–84.
  • Fichorova RN, Cronin AO, Lien E, Anderson DJ, Ingalls RR. Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signaling. J Immunol. 2002; 168: 2424–32.
  • Fichorova RN, Anderson DJ. Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol Reprod. 1999; 60: 508–14. 10.3402/mehd.v24i0.19703.
  • Fichorova RN, Yamamoto HS, Delaney ML, Onderdonk AB, Doncel GF. Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. MBio. 2011; 2: e00168–11.
  • Fichorova RN, Desai PJ, Gibson FC 3rd, Genco CA. Distinct proinflammatory host responses to Neisseria gonorrhoeae infection in immortalized human cervical and vaginal epithelial cells. Infect Immun. 2001; 69: 5840–8. 10.3402/mehd.v24i0.19703.
  • Fichorova RN, Trifonova RT, Gilbert RO, Costello CE, Hayes GR, Lucas JJ, et al. Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. Infect Immun. 2006; 74: 5773–9. 10.3402/mehd.v24i0.19703.
  • Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007; 34: 864–9. 10.3402/mehd.v24i0.19703.
  • Chu T-Y, Hsiung CA, Chen C-A, Chou H-H, Ho C-M, Chien T-Y, et al. Post-coital vaginal douching is risky for non-regression of low-grade squamous intraepithelial lesion of the cervix. Gynecol Oncol. 2010; 120: 449–53. 10.3402/mehd.v24i0.19703.
  • Schwebke JR, Richey CM, Weiss HL. Correlation of behaviors with microbiological changes in vaginal flora. The Journal of infectious diseases. 1999; 180: 1632–6. 10.3402/mehd.v24i0.19703.
  • Pavlova SI, Tao L. In vitro inhibition of commercial douche products against vaginal microflora. Infect Dis Obstetr Gynecol. 2000; 8: 99–104.